RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @AStullkowski: @JonGordon11 @IsaacDovere A study just came out showing that natural immunity prevented Covid in 100%. https://t.co/PAe0…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @BallouxFrancois: New study following 12,541 healthcare workers for #COVID19 re-infection over 31 weeks published in NEJM. Natural immun…
@sickofi42740715 When the naturally acquired immunity is 100% effective at prevention for at least 6 months, compared to at least 3 months with the vax. It's all the media hype and hysteria.. people haven't been presented with the reality. https://t.co/E
RT @BallouxFrancois: New study following 12,541 healthcare workers for #COVID19 re-infection over 31 weeks published in NEJM. Natural immun…
RT @BallouxFrancois: New study following 12,541 healthcare workers for #COVID19 re-infection over 31 weeks published in NEJM. Natural immun…
@JonGordon11 @IsaacDovere A study just came out showing that natural immunity prevented Covid in 100%. https://t.co/PAe0hi0mLG
RT @BallouxFrancois: New study following 12,541 healthcare workers for #COVID19 re-infection over 31 weeks published in NEJM. Natural immun…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @OrdoMedicus: Tweet przed rozpoczęciem szczepień na Covid.
Tweet przed rozpoczęciem szczepień na Covid.
RT @BallouxFrancois: New study following 12,541 healthcare workers for #COVID19 re-infection over 31 weeks published in NEJM. Natural immun…
RT @BallouxFrancois: New study following 12,541 healthcare workers for #COVID19 re-infection over 31 weeks published in NEJM. Natural immun…
RT @BallouxFrancois: New study following 12,541 healthcare workers for #COVID19 re-infection over 31 weeks published in NEJM. Natural immun…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
RT @gerdosi: New mRNA vaccine technologies may offer 94-95 % efficacy. What an achievement of 21st century science! On the other hand, good…
@wilted_prose @jkenney This is a nice paper that says we get about 6 months of immunity. AB is SCREWED. https://t.co/xu61UuxEiw
@keatsie777 @DrHoenderkamp @MattHancock @BorisJohnson Umm, yes there is... https://t.co/0W9oZMr5wK
@warpthumr63 @EOrbius @BaileyHollee @CDCgov Natural infection gives similar protection against future infection that is given by the vaccines. There are plenty of real world studies supporting. Chance of reinfection is low and when it does happen, not as
@NIZP_PZH @Ipsos @DIAGNOSTYKA_lab Publikacja z NEJM z 11/02 - wśród pracowników szpitali Oxford University - na 1265 osób z IgG w ciągu 6-mcy 2 miały PCR+. Bez objawów. https://t.co/PuqulMpK5R https://t.co/VKjiUCt4aK
Natural immunity is robust. Eight months after. No vaccine needed — its fine if people want it, but not mandatory.
Also important: vaccine-induced immunity is likely more durable and is stronger than natural immunity (esp if you had a mild case of #covid19). Presence of antibodies correlates with long-lasting protection. Eg https://t.co/qfIcOyVcQQ https://t.co/1ZAJytt
RT @GlobalPHObserv: .@JHSPH_NCRC Summary: This study helps shed light on the relatively low incidence of #SARSCoV2 #reinfection among tho…
RT @GlobalPHObserv: .@JHSPH_NCRC Summary: This study helps shed light on the relatively low incidence of #SARSCoV2 #reinfection among tho…
RT @GlobalPHObserv: .@JHSPH_NCRC Summary: This study helps shed light on the relatively low incidence of #SARSCoV2 #reinfection among tho…
RT @GlobalPHObserv: .@JHSPH_NCRC Summary: This study helps shed light on the relatively low incidence of #SARSCoV2 #reinfection among tho…
RT @GlobalPHObserv: .@JHSPH_NCRC Summary: This study helps shed light on the relatively low incidence of #SARSCoV2 #reinfection among tho…
.@JHSPH_NCRC Summary: This study helps shed light on the relatively low incidence of #SARSCoV2 #reinfection among those with #antibodies for up to 6 months. https://t.co/xgKYc3MxLu
@villamizar @Astianax_ No... Por la misma razón que una dosis de vacuna no es tan buena cómo dos. Brinda una forma de protección (se midió que 83% en personal de salud con anticuerpos positivos https://t.co/CO3CGJOruL) pero reinfectarse de virus respirator
Summary: This study helps shed light on the relatively low incidence of #SARSCoV2 #reinfection among those with #antibodies for up to 6 months. https://t.co/V7PWFFJz00
RT @boticariors: Datos a favor de la baja probabilidad de reinfección tras expresión de IgG. La caracterización inmunológica del 1er episo…
RT @HollyBell8: Bottom line: Having had COVID provides at least as much protection from reinfection as the Pfizer vaccine. Antibody Status…
Bottom line: Having had COVID provides at least as much protection from reinfection as the Pfizer vaccine. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers | NEJM https://t.co/DR1hMeaTPp
RT @ccanesth: #CritCareAnesthesiology #JournalWatch Incidence and seroconversion of SARS-CoV-2 infection in health care workers in the UK.…
RT @ccanesth: #CritCareAnesthesiology #JournalWatch Incidence and seroconversion of SARS-CoV-2 infection in health care workers in the UK.…
@Nthn90 @caelisangelus Verworven immuniteit blijft aanwezig en blijft beschermen, dat is zeer goed aangetoond in een prospectieve studie: https://t.co/OV3FYbyqPm
#CritCareAnesthesiology #JournalWatch Incidence and seroconversion of SARS-CoV-2 infection in health care workers in the UK. The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a reduced risk COVID-19 for 6 months. @NEJM http
@muradbanaji Thanks; interesting thread. This is a question we’re struggling with in India too:
@AntWadebridge @MLevitt_NP2013 To support that you'd have to show 100% reinfection rate. How many confirmed reinfections have there been? Last article I saw said 31. In fact an infection seems to confer immunity even in people with a large exposure. http
RT @ahmadtaqi74: دراسة جديدة تابعت ١٢٥٤١ من الطواقم الطبية في بريطانيا لمدة ٣١ اسبوع، نشرت في مجلة NEJM العلمية. من اصيب من الطواقم، حالتين…
@Malbuijan @KUWAIT_MOH الاغلب عندك مناعة اكثر من ٦ اشهر
@KVarming En undersøgelse af 12.000 smittede sundhedsfaglige viste, at 100% var beskyttet mod gensmitte. SSI er fuld af løgn, igen. https://t.co/YjeriadnVM
@MarionKoopmans @ralfdkkr @thierrybaudet "There were no symptomatic infections in workers with anti-spike antibodies." "The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfectio
RT @WreckingBall75: @ProfessorF Study by the New England journal of Medicine. Looked at over 12,000 healthcare workers, who were previously…
@Thomas_Wilckens @WHO This brief note is dated on 24 apr. 2020. We do have evidence, that reinfections are rare and immunity after infection is comparable with best vaccine effectiveness estimates. https://t.co/ClxCmbS4Bs https://t.co/gPkxumxqY2
@ChampersBE oei, zo vreemd, terwijl nu toch blijkt dat merendeel van de mensen hun antistoffen houden. Hopelijk krijg je dan wel antistoffen na vaccinatie. https://t.co/6VcKyj4xgP
RT @DiseaseEcology: Current dogma is that protection from reinfections is 80-90% (like this study) but reinfections are mild or asymptomati…
RT @DiseaseEcology: Note that re-infection is actually not uncommon. 3 studies suggest protection from prev exposure is only 82%: https://t…
RT @DiseaseEcology: Current dogma is that protection from reinfections is 80-90% (like this study) but reinfections are mild or asymptomati…
@ProfessorF Study by the New England journal of Medicine. Looked at over 12,000 healthcare workers, who were previously diagnosed with cover, over 31 weeks. Only 2 were reinfected. Both asymptomatic. It’s insane that new(good) data is often disregarded.
RT @DiseaseEcology: Current dogma is that protection from reinfections is 80-90% (like this study) but reinfections are mild or asymptomati…
RT @DiseaseEcology: Note that re-infection is actually not uncommon. 3 studies suggest protection from prev exposure is only 82%: https://t…
RT @DiseaseEcology: Note that re-infection is actually not uncommon. 3 studies suggest protection from prev exposure is only 82%: https://t…
RT @DiseaseEcology: Current dogma is that protection from reinfections is 80-90% (like this study) but reinfections are mild or asymptomati…
RT @DiseaseEcology: Current dogma is that protection from reinfections is 80-90% (like this study) but reinfections are mild or asymptomati…
RT @DiseaseEcology: Current dogma is that protection from reinfections is 80-90% (like this study) but reinfections are mild or asymptomati…
Current dogma is that protection from reinfections is 80-90% (like this study) but reinfections are mild or asymptomatic (https://t.co/PZmXnjgK97). But here 50% were symptomatic & 5 of 31 symptomatic reinfections needed hospitalization (fraction for ne
オックスフォード大学病院の医療従事者のうち、抗スパイク抗体、抗ヌクレオカプシド抗体(IgG)陽性者は陰性者よりも再感染率が低いと。 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers | NEJM https://t.co/qF8kxU9G9R
RT @semeg_es: Incidencia reinfección #COVID en personal sanitario según su nivel de IgG. https://t.co/MtKUkeoTBm
@adrianarg_nm @benshapiro Hi because current restrictions allow these types of gatherings. There’s also more evidence of long term immunity other than the 3 months than were originally thought. Also, the hospital system aren’t overwhelmed. https://t.co/n
Pomembni odprti vprašanji sta torej še, kako dobro nas ščiti celična imunost, koliko je pravzaprav ponovnih okužb, kako težke so in ali nove različice povzročajo težji potek bolezni. (14/22) https://t.co/N7l6U8ePCm https://t.co/hMdWZeaEhN
@zondagmetlubach "There were no symptomatic infections in workers with anti-spike antibodies." "The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 month
RT @BorisOrduz: Estudio sobre la variante #SARSCoV2 en Manaos mostrando que P1 puede ser más transmisible y es capaz de evadir la inmunidad…